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The inﬂammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative col-
itis (UC), are chronic inﬂammatory disorders of the intestine. The prevalence in the United
States is greater than 200 cases per 100,000, with the total number of IBD patients
between 1 and 1.5 million. CD may affect all parts of the gastrointestinal tract, from
mouth to anus, but most commonly involves the distal part of the small intestine or
ileum, and colon. UC results in colonic inﬂammation that can affect the rectum only, or
can progress proximally to involve part of or the entire colon. Clinical symptoms include
diarrhea, abdominal pain, gastrointestinal bleeding, and weight loss. A serious long-term
complication of chronic inﬂammation is the development of colorectal cancer. A genetic
basis for IBD had long been recognized based on the increased familial risk. However,
signiﬁcant discordance for CD in twins, and a much less robust phenotypic concordance
for UC, suggested additional factors play a role in disease pathogenesis, including envi-
ronmental factors. In the past several years, progress in understanding the molecular
basis of IBD has accelerated, beginning with the generation of animal models of colitis
and progressing to the identiﬁcation of speciﬁc genetic markers from candidate gene,
gene linkage, and genome-wide association analyses. Genetic studies have also resulted
in the recognition of the importance of environmental factors, particularly the crucial role
of the gut microbiota in CD and UC. Altered immune responses to the normal intesti-
nal ﬂora are key factors in IBD pathogenesis. In this research topic, the genetic basis of
IBD, the genetic and cellular alterations associated with colitis-associated colon cancer,
and the emerging role of the intestinal microbiota and other environmental factors will be
reviewed.
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INTRODUCTION
The inﬂammatory bowel diseases (IBD), including Crohn’s disease
(CD) and ulcerative colitis (UC), are chronic inﬂammatory disor-
ders of the intestine. The prevalence in the United States is greater
than 200 cases per 100,000 for each disorder, with the total num-
ber of IBD patients between 1 and 1.5 million (Kappelman et al.,
2007; Loftus Jr., 2007). CD may affect all parts of the gastrointesti-
nal tract, from mouth to anus, but most commonly involves the
distal part of the small intestine or ileum, and colon. UC results
in colonic inﬂammation that can affect the rectum only (procti-
tis) or can cause continuous disease from the rectum proximally,
to involve part of or the entire colon. Clinical symptoms include
diarrhea, abdominal pain, gastrointestinal bleeding, and weight
loss. A serious long-term complication of chronic inﬂammation
is the development of colorectal cancer (CRC).
A genetic basis for IBD had long been recognized based on
the increased familial risk, with a 5–30% incidence in families of
affected individuals (Duerr, 2002) as well as 50–75% phenotypic
concordance in monozygotic twins with CD (Tysk et al., 1988). A
family history of IBD ismore commonly found inpatientswithCD
compared to UC (Duerr, 2002). However, signiﬁcant discordance
for CD in twins, as well as a much less robust phenotypic con-
cordance for UC in twins (Tysk et al., 1988; Orholm et al., 2000),
also suggested additional factors play a role in disease pathogene-
sis, including a signiﬁcant impact of environmental factors. In the
past several years, progress in understanding the molecular basis
of IBD has accelerated markedly, beginning with the generation
of rodent transgenic and mouse knockout models of colitis and
progressing to the identiﬁcation of speciﬁc genetic markers from
candidate gene approaches, gene linkage, and genome-wide asso-
ciation analyses (Tysk et al., 1988; Duerr et al., 2006; Barrett et al.,
2008; Fisher et al., 2008; Anderson et al., 2009; Silverberg et al.,
2009; Franke et al., 2010). It has become increasingly clear that IBD
is a polygenic, complex disorder with region- and ethnic-speciﬁc
differences in genetic risk factors (Abraham and Cho, 2009). In
addition, genetic studies have resulted in the recognition of the
importance of environmental factors, particularly focusing on the
critical importance of the gut microbiota in CD and UC (Nell
et al., 2010). Altered immune responses to the normal intestinal
ﬂora of the gut are key factors in CD pathogenesis.
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Chronic inﬂammation is also associated with malignancy and
has been proposed to be a major contributor to a multitude of
cancers (Coussens and Werb, 2002; Kundu and Surh, 2008; Man-
tovani et al., 2008; Danese and Mantovani, 2010; Solinas et al.,
2010). Chronic colonic inﬂammation from UC or CD results in a
well-recognized increased risk of colon carcinogenesis (Bernstein
et al., 2001; Eaden et al., 2001; Itzkowitz andYio, 2004; Ullman and
Itzkowitz, 2011). CD is also associated with an increased risk of
small bowel adenocarcinoma, due to chronic inﬂammation of the
small intestine. The cumulative probability of CRC in UC patients
has been shown in meta-analysis to range from 2% after 10 years
of disease, up to 18% after 30 years of disease (Eaden et al., 2001;
Feagins et al., 2009; Westbrook et al., 2010). Patients with Crohn’s
colitis also have an increased cumulative risk for CRC, from 2.9%
at 10 years to 8.3% after 30 years of disease (Canavan et al., 2006).
The risk of carcinogenesis is related to severity, extent, and dura-
tion of disease (Rutter et al., 2004). Patients are advised to undergo
colonoscopy with a speciﬁc biopsy protocol, performed every
1–2 years after 8–10 years of disease to detect dysplasia and rule
out carcinogenesis. Unlike in sporadic colorectal carcinoma, in
which the dysplastic lesion is an adenomatous polyp, dysplasia
in IBD can be ﬂat or polypoid. Flat lesions can be particularly
difﬁcult to detect endoscopically, and more sensitive markers of
dysplasia are still lacking and represent a major focus of current
research. Because of the frequency of IBD, the early onset of disease
and the signiﬁcantly increased risk for carcinogenesis, the health,
emotional, and economic burden is quite high.
In this review, the genetic basis of IBD, the genetic and cellular
alterations associated with chronic inﬂammation-induced colon
cancer, and the emerging role of the intestinal microbiota and
other environmental factors will be reviewed.
CLINICAL CHARACTERISTICS OF THE INFLAMMATORY
BOWEL DISEASES
CLINICAL CHARACTERISTICS COMMON TO ULCERATIVE COLITIS
AND CROHN’S DISEASE
The peak age of incidence for IBD is between 16 and 30 years
(Kuster et al., 1989). Both UC and CD can affect the colon,
and patients with either UC or CD have an increased risk of
colitis-associated cancer (CAC) after 8–10 years from the time
of diagnosis. Symptoms of active disease include diarrhea and
abdominal pain. Although both CD and UC patients can experi-
ence gastrointestinal bleeding, inUChematochezia or the presence
of visible bleeding is more common than in CD, in which there
is occult or microscopic blood loss. Extraintestinal manifestations
of IBD include arthralgias and arthritis, skin diseases such as ery-
thema nodosum and pyoderma gangrenosum, ocular disorders
including uveitis and iritis, and sclerosing cholangitis, in which
there is inﬂammation of the liver’s bile ducts. Urinary excretion of
oxalate may be elevated in patients with CD, resulting in kidney
stones, in patients who have not had a colectomy. Both UC and
CD patients may develop strictures in the colon (UC or CD) or
small bowel (CD only).
CLINICAL CHARACTERISTICS SPECIFIC TO CROHN’S DISEASE
Patients with CD suffer the consequences of a transmural inﬂam-
matory process and thus are at risk for ﬁstulizing disease. Fistulas,
which are communications between the gastrointestinal tract and
other organs, may form between the bowel and bladder or the
vagina, (e.g., enterovesicular or recto-vaginal ﬁstulas), from the
intestines to the skin (enterocutaneous ﬁstulas), or from intestine
to intestine (enteroenteric ﬁstulas). Perianal disease is common
and can be debilitating and refractory to treatment. Due to the
transmural nature of the inﬂammatory process and involvement
of the small intestine which is responsible for nutrient absorp-
tion, patients with CD are more prone to weight loss, nutrient
deﬁciencies, and in children, growth retardation, especially after
glucocorticoid therapy. Other serious complications include per-
foration or microperforation of the small or large bowel which
may result in abscess formation. Surgical resection of the colon is
not curative because CD can affect all parts of the gastrointestinal
tract from mouth to anus. Pathological features speciﬁc to CD
include the presence of granulomas on biopsy of the small bowel
or colon.
CLINICAL CHARACTERISTICS SPECIFIC TO ULCERATIVE COLITIS
Colonic inﬂammation in UC is continuous, beginning in the
rectum. Gross gastrointestinal bleeding is much more common
in UC. The development of toxic megacolon is a dreaded com-
plication of active inﬂammation, which may lead to emergent
colectomy. Unlike in CD, colectomy is curative in UC.
MOUSE MODELS OF INFLAMMATORY BOWEL DISEASE
CHEMICAL MODELS
Mouse models of colitis and CAC have proven in selected cir-
cumstances to be relevant to the pathogenesis of these disorders
in humans, have led to the identiﬁcation of critical genetic fac-
tors and have provided a means for understanding the role
of speciﬁc genes identiﬁed by linkage or genome-wide associa-
tion studies. Two of the most widely used, non-genetic colitis
models are the dextran sodium sulfate (DSS)-induced chemi-
cal injury model, and the trinitrobenzene sulfonic acid (TNBS)
hapten-induced model (Strober et al., 2002). These have been par-
ticularly useful in identifying and studying the role of genetic
factors that modify colitis, because both DSS and TNBS can be
administered to genetically altered (knockout or transgenic) mice
to rapidly induce colonic inﬂammation and ulceration resem-
bling UC (Strober et al., 2002). DSS in drinking water induces
an acute colitis within 5 days of exposure, and can also be uti-
lized to mimic chronic colitis after repeated exposures. DSS in
combination with azoxymethane (AOM) can be utilized to gen-
erate a mouse model of CAC (Greten et al., 2004; Neurath and
Finotto, 2009). TNBS is administered by enema and results in
a hapten-induced, interleukin-12 (IL-12) driven colitis (Neurath
and Finotto, 2009).
GENETIC MODELS
The earliest murine genetic models of IBD were generated in mice
in which the T cell receptor was inactivated (Mombaerts et al.,
1993), IL-10 (Kuhn et al., 1993) or IL-2 (Sadlack et al., 1993) was
deleted, or tumor necrosis factor-alpha (TNFαARE mice) was
over-produced. These mice develop colitis after variable lengths of
time, and a seminal discovery was the observation that in almost
every genetic model, the microbiota are required for induction
Frontiers in Immunology | Inﬂammation May 2012 | Volume 3 | Article 107 | 2
“ﬁmmu-03-00107” — 2012/5/7 — 16:51 — page 3 — #3
Rubin et al. Chronic intestinal inﬂammation and cancer
of colitis (reviewed in Nell et al., 2010). Mice raised in either
a germ-free environment (e.g., IL-10 mice; Sellon et al., 1998)
or treated with antibiotics were protected from colitis. Subse-
quently, a plethora of mouse IBD models have been described,
resulting from gene knockout or transgenic overexpression. As
summarized in Rosenstiel et al. (2009), some mouse models cor-
relate well with human disease risk loci or associated pathways,
whereas others do not yet have clear relevance to human clinical
syndromes.
GENETICS OF INFLAMMATORY BOWEL DISEASE
Exciting advances in the understanding of the complex genet-
ics of IBD have resulted from comprehensive genetic studies
including linkage and genome-wide association analyses. These
have led to the identiﬁcation of several predicted as well as
novel pathways involved in CD and UC pathogenesis. For exam-
ple, the critical roles of innate immunity and autophagy as
well as epithelial barrier function have been supported by the
identiﬁcation of risk alleles in genes from these pathways, by
genome-wide association studies (e.g., Duerr et al., 2006; Bar-
rett et al., 2008; Silverberg et al., 2009). A complete list of genetic
loci linked to IBD susceptibility (Kaser et al., 2010) shows that
some are speciﬁc to CD, some to UC, and some are linked to both
diseases.
INNATE IMMUNITY
NOD2/CARD15
A seminal discovery in unraveling the complex genetics underly-
ing CD was that mutations in the NOD2/CARD15 gene locus are
associated with risk for CD in Caucasian populations of European
ancestry (Hugot et al., 2001; Ogura et al., 2001), and particularly
for ileal disease (Lesage et al., 2002). Mutations in NOD2 are not
sufﬁcient for generating CD, as a signiﬁcant proportion of the
normal population has NOD2 mutations but are not affected by
this disorder. However, individuals who are heterozygous for a
NOD2 polymorphism have an increased risk of CD by a fac-
tor of 1.7–4, and homozygosity confers a risk factor of 11–27
(Economou et al., 2004). NOD2/CARD15 is a member of a family
of cytosolic receptors containing a central nucleotide binding and
oligomerization domain (NOD), an N-terminal effector binding
domain, and leucine-rich repeats. These and other pattern recog-
nition receptors, expressed in the epithelium and in a variety of
immune cells, have important functions in innate immunity, par-
ticularly in regulating responses to intracellular pathogens and
other exogenous injury-inducing stimuli. NOD2 recognizes com-
ponents of the bacterial cell wall and elicits an NF-κB response,
and also mediates the release of defensins, which are antimicrobial
peptides. Mutations which impair NOD2 function result in defec-
tive downregulation of pro-inﬂammatory cytokines that normally
occurs during chronic NOD2 stimulation (Hedl et al., 2007). In
addition, in macrophages, others have shown that NOD2 is a neg-
ative regulator of Toll-like receptor 2 (TLR2)-mediated activation
of NF-κB-c-Rel (Watanabe et al., 2004). However, the mechanisms
by which loss of function mutations result in CD are still under
investigation (Abraham and Cho, 2009). The discovery of this
association led to further recognition of the importance of the
microbiome in CD pathogenesis.
Autophagy genes ATG16 autophagy related 16-like 1 (ATG16L1)
and immunity related GTPase family M
Genome-wide association studies have shown that polymor-
phisms in the ATG16L1 gene (Hampe et al., 2007) and sequence
variants in the IRGM gene (Parkes et al., 2007) are linked to CD.
These genes encode proteins that are critical for autophagy, a
process that mediates degradation of intracellular proteins via
vesicle-mediated delivery to the lysosome (reviewed in Glick et al.,
2010; Huett et al., 2010). Autophagy is particularly important
for defense against intracellular pathogens. A mouse model of
ATG16L1 deﬁciency showed Paneth cell dysfunctionwith aberrant
exocytosis, as well as an altered transcriptional proﬁle, character-
ized by increased expression of pro-inﬂammatory cytokines and
lipid metabolism genes. Patients with CD have a similar Paneth
cell phenotype (Cadwell et al., 2008). An important observation
derived from the ATG16L1 mouse model was that viral infection
with murine norovirus, as well as the presence of commensal
bacteria, were required for generating these speciﬁc Paneth cell
abnormalities (Miller et al., 2008). Germ-free mice have normal
Paneth cells and viral infection in the presence of commensal
bacteria induced the characteristic changes in Paneth cell func-
tion. IRGM functions to protect cells from mycobacteria (Singh
et al., 2006). These data provide further support for the hypothe-
sis that microbial/viral interactions with the intestinal mucosa are
required for disease generation, and suggest that combinatorial
models for IBD pathogenesis are most relevant for the study of
human disease pathogenesis.
Intelectin 1 or ITLN1
Genome-wide association studies have also identiﬁed an associ-
ation between intelectin 1 and CD. Intelectin 1 is a lectin that
recognizes galactofuranosyl residues in bacterial cell walls and is
identical to human lactoferrin receptor (Tsuji et al., 2001). It is a
lipid raft protein that resides in the enterocytic brush border and
is also expressed in Paneth and goblet cells of the small bowel
(Wrackmeyer et al., 2006). Its presumed function is to protect
from parasitic infection and offer cytoprotection from bacterial
translocation.
INFLAMMATORY/CYTOKINE SIGNALING PATHWAYS
IL-23 RECEPTOR, INTERLEUKIN 12B, AND OTHER GENES INVOLVED
IN IL-23 SIGNALING AND T HELPER CELL 17 FUNCTION
Genome-wide association studies have shown an association
between IL23R and CD (Duerr et al., 2006). This gene encodes a
subunit of the IL-23 receptor (IL-23R) complex, which consists of
the IL-23R and the IL-12 receptor B1. IL-23 is a pro-inﬂammatory
cytokine that results in activation of Janus-associated kinase (JAK)
2 and signal transducers and activators of transcription 3 (STAT3),
which are important downstreammediators of inﬂammation. The
likely relevance of IL-23R to CD is suggested by its known bio-
logical functions, e.g., IL-23 expression is required for murine
colitis (Yen et al., 2006), and IL-23 is important for T helper cell
17 (Th17) cell function and production of IL-17. IL-17 expres-
sion is increased in colons from patients with UC and CD (Fujino
et al., 2003), and other members of IL-23R regulated pathways are
linked to both UC and CD, e.g., STAT3, JAK 2, and IL12B (Bar-
rett et al., 2008). In addition, the chemokine receptor CCR6 is also
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implicated in CD, and is expressed by immature dendritic cells and
memory T cells (Barrett et al., 2008).
Interleukin-10
Interleukin-10 is an anti-inﬂammatory cytokine that has long been
postulated to play a role in IBD. One of the ﬁrst mouse mod-
els of IBD resulted from the generation of the IL-10 knockout
mouse, which develops spontaneous inﬂammation (Kuhn et al.,
1993), and which is dependent upon the presence of gut bac-
teria. Regulatory T cells (Tregs) express IL-10; selective deletion
of IL-10 expression in Tregs results in spontaneous colitis and
inﬂammation at other epithelial surfaces including skin and lungs
(Rubtsov et al., 2008). Genome-wide association studies for UC
have shown SNPs ﬂanking the IL-10 gene to be linked to UC
(Franke et al., 2008b). In addition, patientswith early onset IBD (at
less than 1 year of age) had mutations in the IL10RA and IL10RB
genes, which resulted in abrogated STAT3 phosphorylation from
deﬁcient IL-10 signaling (Glocker et al., 2009). Interestingly, the
phenotype of these patients is closest to CD, yet genome-wide
association studies have not identiﬁed IL-10 as a susceptibility
locus. However, these data all support a key role for IL-10 in
IBD and suggest that future therapeutic trials with IL-10 may be
warranted.
NKX2.3
Genome-wide association studies have shown that this home-
odomain transcription factor is associated with CD and UC
(Barrett et al., 2008; Franke et al., 2008a). Mice that are null
for Nkx2.3 have defective splenic and intestinal development.
Homozygous null mice exhibit a marked delay in villus forma-
tion with crypt hypoproliferation. A subset of mice survive to
adulthood and show massive hyperproliferation of the gut with
decreased Bmp2 and Bmp4 expression (Pabst et al., 1999). Splenic
development is markedly abnormal, in these mice, resulting in
either small or completely absent spleens. Although the pheno-
type associated with NKX2.3 mutations in humans has not been
deﬁned, mouse models suggest gut epithelial or splenic functional
defects.
T CELL-MEDIATED RESPONSES
T helper cells differentiate into two distinct subtypes, Th1 and
Th2 cells. These cells produce characteristic sets of cytokines.
Many years of investigation has shown that Th1 cytokines are
expressed in CD, whereas UC is a Th2 cytokine-mediated disease.
A review of this vast body of research is beyond the scope of this
manuscript, and is discussed indetail in other reviews (e.g., Strober
and Fuss, 2011).
ENVIRONMENTAL RISK FACTORS
SMOKING
Smoking has emerged as one of the critically important risk fac-
tors for IBD,with an interesting paradoxical relationship forUCvs.
CD disease activity. Smoking clearly increases the risk of CD activ-
ity (Calkins, 1989) and increases risk of recurrence after surgery
(Unkart et al., 2008), yet appears to be protective for UC (Harries
et al., 1982; Calkins, 1989). Nicotine has been studied as a primary
treatment for UC (Pullan et al., 1994; Sandborn et al., 1997). Car-
bon monoxide, an important component of cigarette smoke, has
been shown to suppress colonic pro-inﬂammatory cytokine pro-
duction, and increase IL-10 secretion, through heme oxygenase-1
dependent pathways (Sheikh et al., 2011).
THE MICROBIOME
Bacterial, mycobacterial, or viral infections have long been pos-
tulated to be important in IBD pathogenesis (Lidar et al., 2009).
A common feature of almost all rodent models of IBD is that
treatment with antibiotics or rederivation of knockout or trans-
genic mice into germ-free conditions markedly mitigates disease
activity (e.g., Taurog et al., 1994; Strober et al., 2002). Antibi-
otics can ameliorate disease activity in humans, and for certain
complications of CD such as ﬁstulizing disease, metronidazole
is an important therapeutic agent. Viral infection is required
to generate the Paneth cell defects found in ATG16L1 mice
(Cadwell et al., 2010) suggesting that in addition to human bacte-
rial microbiota, viral or fungal commensals may play a role in IBD
pathogenesis.
Associations with single microorganisms
Microbial association studies in mouse models and analysis of
intestinal mucosa or blood from patients with CD have impli-
cated single pathogenic bacterial species in IBD pathogenesis,
although none have yet been proven to be causative (reviewed
in Lidar et al., 2009; Reiff and Kelly, 2010). The microorgan-
isms most frequently implicated include Mycobacterium avium
subspecies paratuberculosis, Saccharomyces cerevisiae, Candida
albicans, adherent enteroinvasive Escherichia coli, and Chlamydia
pneumoniae.
The microbiome in normal intestine and in inﬂammatory
bowel disease
Recent discoveries implicating genes such as NOD2 in the patho-
genesis of CD have led to the recognition that the pathogenesis
of IBD involves loss of tolerance to commensal organisms and
enhanced immune responses to bacterial antigens. The intestine
is colonized by the largest bacterial burden in the body, con-
taining approximately 100 trillion organisms (Gill et al., 2006).
Bacteria belonging to the Firmicutes (Gram-positive bacteria)
and Bacteroidetes (Gram-negative bacteria) phyla are the two
major groups in mammalian intestine (Backhed et al., 2005; Turn-
baugh et al., 2007). Proteobacteria (which include Helicobacter
and Escherichia) and Actinobacteria are also signiﬁcant con-
tributors to the gut ﬂora. Multiple studies have shown that
the gut microbiota is altered in IBD patients. For example,
biopsy samples from CD patients were used to prepare bac-
terial DNA which was ampliﬁed using universal bacterial 16S
rRNA primers (Gophna et al., 2006). A signiﬁcant increase in
Proteobacteria and Bacteroidetes was found in CD patients com-
pared to controls, with a decrease in Clostridia. Metagenomic
approaches were used to analyze fecal samples from Crohn’s
patients and healthy donors, and revealed reduced complexity
of the Firmicutes in affected patients (Manichanh et al., 2006).
Evaluation of the microbial populations in surgically resected tis-
sue samples of small bowel and colon from Crohn’s, UC, and
non-IBD controls, by rRNA sequence analysis, showed that spe-
ciﬁc ﬂora were not enriched in small bowel or colon from IBD
patients. However, a subset of IBD samples showed alterations
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in the representation of the Bacteroidetes and Firmicutes (Eck-
burg and Relman, 2007; Frank et al., 2007, 2011). Analysis of
fecal samples from IBD patients compared to healthy subjects
(Qin et al., 2010.) showed reduced bacterial diversity and altered
bacterial species abundance, using metagenomic sequencing
methods
Role of Toll-like receptors and nucleotide-binding
oligomerization domain protein-like receptors
Toll-like receptors and NLRs are innate receptors that play an
important role in recognizing commensal bacteria. Recognition
of commensals by TLRs and NLRs has been shown to be critical
formaintaining intestinal epithelial integrity and homeostasis. For
example, mice deﬁcient in the adaptor protein, MyD88, develop
severe colitis followingDSS administration (Rakoff-Nahoumet al.,
2004). Inﬂammasomes composed of NLR proteins sense damage-
associated molecular patterns. NLRP6 inﬂammasome-deﬁcient
mice had more severe colitis, reduced IL-18 levels, and altered
gut microbiota (Elinav et al., 2011).
COLITIS/INFLAMMATION-ASSOCIATED DYSPLASIA
AND CANCER
RELATIONSHIP TO COLORECTAL CANCER
The pathogenetic mechanisms underlying CAC compared to
familial or sporadic CRC have signiﬁcant similarities, but major
differences have also been recognized (Feagins et al., 2009; Terzic
et al., 2010; Ullman and Itzkowitz, 2011). Whereas dysplasia in
CRC is focal, multiple areas of the colon are often involved in
CAC, indicating a broader “ﬁeld effect.” Linkage analyses of fam-
ilies with rare, inherited early-onset CRC led to the identiﬁcation
of gene mutations which are highly relevant to the much more
common sporadic CRC. In many circumstances, mutations in
these genes also occur in CAC, but at a different stage of the
disease, and other gene mutations are speciﬁc to CRC only. A
seminal discovery in CRC pathogenesis was that inherited muta-
tions in the adenomatous polyposis coli (APC) gene result in
familial adenomatous polyposis or FAP, in which affected patients
develop hundreds of adenomatous polyps and are at high risk
for early death from CRC (Groden et al., 1991). APC mutations
occur in sporadic CRC and are one of the earliest events in CRC
pathogenesis. APC mutations are also found in CAC, but gener-
ally occur much later in the disease course (Redston et al., 1995;
Tarmin et al., 1995; Aust et al., 2002). On the other hand, KRAS
and DCC/DPC4 mutations occur in both CAC and CRC (Ull-
man and Itzkowitz, 2011). P53 mutations are commonly found
in CACs. P53 mutation is an early event that precedes loss of
heterozygosity and is highly associated with aneuploidy (Brent-
nall et al., 1994). Chronic inﬂammation associated with increased
pro-inﬂammatory cytokine release and signaling plays a critical
role in the initiation of CAC, but sporadic CRC tumors also
exhibit inﬂammatory inﬁltrates and activated immune response
pathways (Terzic et al., 2010). These observations have led to
the postulation that inﬂammation promotes tumorigenesis both
extrinsically (driven by chronic inﬂammatory conditions such as
IBD) and intrinsically (driven by inﬂammation and inﬂammatory
cells recruited to and contained within tumors; Mantovani et al.,
2008; Danese and Mantovani, 2010).
MOUSE MODELS OF COLITIS-ASSOCIATED CANCER
One of the most widely utilized mouse models of CAC is the
AOM/DSS model (Becker et al., 2004; Greten et al., 2004; Suzuki
et al., 2006; Neufert et al., 2007; Tanaka et al., 2008); AOM is a
chemical carcinogen that acts by alkylation of DNA. It is fur-
ther metabolized by the liver after intraperitoneal injection and
is excreted in the bile. Additional metabolism by the bacterial ﬂora
further activates its carcinogenicity (Neufert et al., 2007). Multi-
ple injections of AOM result in distal colonic tumorigenesis with
histologic characteristics similar to human CRC. To mimic CAC,
mouse models were developed that use AOM in combination with
DSS, which when included in the drinking water, induces coli-
tis, as above. The ﬁrst models used AOM injection followed by
one cycle of DSS. However, to further mimic states of chronic
inﬂammation, AOM injection was combined with three cycles of
DSS,which induces a chronic colitis. Thismodel accelerates tumor
formation and results in larger tumor size. Of interest, there are
differences in susceptibility among mouse strains (Suzuki et al.,
2006) and the formation of tumors in the same strain may vary
among mouse facilities, suggesting that tumorigenesis is affected
by microﬂora.
PATHOGENESIS AND MOLECULAR BIOLOGY OF
COLITIS-ASSOCIATED CANCER
Cancer associated with chronic inﬂammation, similar to other
cancers, is characterized by a loss of normal growth regulation,
resulting from a series of genetic mutations and epigenetic alter-
ations in important cancer-related regulatory genes. The cancer
stem cell model postulates that expansion of stem cells occurs
in response to these mutations, resulting in tumor formation.
The mechanisms by which inﬂammation results in carcinogen-
esis are presently the focus of intense research. Multiple pathways
are likely to play a role, including production of reactive oxy-
gen species and cytokine and chemokine expression by immune
cells, which increase the risk of mutagenesis, and interactions
between cancer stem cells and the local tumor microenvironment,
including immune cells and myoﬁbroblasts (Shaker et al., 2010;
Vermeulen et al., 2010; Worthley et al., 2010; Quante et al., 2011;
Shaker andRubin, 2011). Inﬂammation also affectsDNAmethyla-
tion patterns and histone modiﬁcation. Cyclo-oxygenase 2, which
metabolizes arachidonic acid to prostaglandins, exhibits increased
expression in inﬂamed tissues and affects cell proliferation, apop-
tosis, and angiogenesis. Genetic factors also play a role as IBD
patients with a family history of CRC have an additional increase
in risk for CAC, suggesting overlapping mechanisms.
ROLE OF THE MICROBIOME, TLRs, AND NLRs
In addition to playing an important role in IBD, TLRs and
NLRs also contribute to the pathogenesis of CAC. For exam-
ple, MyD88 signaling appears to be protective in the AOM/DSS
model of CAC; Myd88−/− mice had increased polyp numbers
compared to controls, and developed inﬁltrating carcinomas
(Salcedo et al., 2010). In addition, derepression of the inﬂamma-
some in Casp12−/− mice, resulted in enhanced epithelial repair
processes with increased proliferation, increased inﬂammation
and increased susceptibility to AOM/DSS CAC (Dupaul-Chicoine
et al., 2010).
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ROLE OF OXIDATIVE STRESS, CYTOKINES, AND CHEMOKINES
Inﬂammatory cells produce a variety of reactive oxygen and nitro-
gen species which may generate gene mutations and DNA damage,
contributing to carcinogenesis (Kawanishi et al., 2006; Kundu and
Surh, 2008; Mantovani et al., 2008; Colotta et al., 2009). For exam-
ple, mice which sustain DNA damage from inﬂammation and
which are deﬁcient in base excision repair enzymes have increased
tumor multiplicity in the AOM/DSS mouse model of CAC, indi-
cating that inﬂammation can induce DNA damage which in turn
contributes to colon carcinogenesis (Liao et al., 2008; Meira et al.,
2008). Direct genotoxicity was documented in mouse models of
intestinal inﬂammation, which correlated with the degree of sys-
temic and local inﬂammation, and was associated with evidence of
reactive oxygen species-mediated oxidative stress and DNA dam-
age (Westbrook et al., 2010). On the other hand, the role of nitric
oxide is less clear. Mice which lack inducible nitric oxide syn-
thase, the enzyme that generates nitric oxide (iNOS−/− mice),
when bred to IL10−/− mice (which spontaneously develop colitis
and adenocarcinoma with aging), had higher numbers of polyps
compared to IL-10−/− mice alone, suggesting that nitric oxide
may be protective (Zhang et al., 2007). However, increased pro-
duction of reactive oxygen and nitrogen species may also result in
oncogene activation or tumor suppressor inactivation by inducing
mutations in critical regulatory genes. For example, p53 muta-
tions in codons 247 and 248 were found in inﬂamed colons of
UC patients, associated with increased iNOS expression (Hussain
et al., 2000).
The major cytokines that play the best-described role in pro-
moting inﬂammation in CAC include TNFα, IL-1, and IL-6
(Greten et al., 2004; Grivennikov et al., 2009; Shaker et al., 2010).
TNFα signaling via NF-κB pathways mediated downstream by
IL-6 and STAT3 appear to play an important role in this disorder
(Ullman and Itzkowitz, 2011).
GENE SILENCING BY METHYLATION OR BY miRNA
An important mechanism of tumorigenesis is epigenetic silencing
of selected genes such as tumor suppressor genes, by promoter
methylation or by microRNAs (miRNA). These include DNA
mismatch repair (MMR) genes; hypermethylation is thought to
be the mechanism responsible for loss of MMR activity. Loss of
DNA MMR gene activity results in microsatellite instability, which
is characterized by increased frameshift mutation rates. MMR-
deﬁcient tumors account for approximately 15% of all CRCs and
are characterized by a right sided location, have a lymphocytic
inﬁltrate and have a poorly differentiated, mucinous, or signet cell
histologic appearance.
The methylation status of normal, inﬂamed, and dysplastic
colonic tissue has been studied intensively. It has been proposed
that gene methylation may be an early event in inﬂammation-
associated tumorigenesis, and thus can potentially be a sensitive
marker for predicting dysplasia. The methylation status of multi-
ple genes has been examined, and generally, DNA methylation
appears to be more frequent and is seen more commonly in
non-neoplastic mucosa from UC patients with CAC, compared
to non-neoplastic mucosa from UC patients without cancer. For
example, themethylation status of RUNX2 andMINT1was higher
in non-neoplastic tissue of UC patients with CAC compared to
non-neoplastic tissue of UC patients without cancer. In con-
trast, COX-2 was more frequently methylated in colons from UC
patients without cancer compared to UC patients with cancer
(Garrity-Park et al., 2010). Aging is associated with methylation
and silencing of a panel of genes (including the estrogen receptor,
MyoD,p16 exon1, and CSPG2). In non-dysplastic tissues from UC
patients with high grade dysplasia, these genes also showed signif-
icantly higher degrees of methylation, compared to UC patients
without dysplasia (Issa et al., 2001). Methylation of the estrogen
receptor in non-neoplastic epithelium of UC patients with CAC
occurred in a higher percentage compared to UC patients with-
out cancer (Fujii et al., 2005). These data suggest that methylation
status can be used as a biomarker for early detection of dysplasia,
and also may help identify patients who are at increased risk for
neoplasia.
CONCLUSION
Great progress has been made towards identifying the genetic basis
for the IBD, and for understanding the interactions between the
gut luminal/microbial environment and its epithelium. Future
researchwill focus onunderstanding the function of identiﬁed dis-
ease risk genes and developing new targeted therapies. The burden
of CAC continues to be high, and current research is focused on
developing more sensitive markers of dysplasia. Intensive efforts
will be focused on further delving into themechanisms underlying
the initiation of chronic inﬂammation-associated cancer, includ-
ing the role of stromal–epithelial interactions within the unique
environment of the gastrointestinal tract. As our understanding of
gastrointestinal cancer stem cells progresses, so will our ability to
optimally target the interactions between tumor epithelium and
its microenvironment in CAC.
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